Efung News | HighLight Pharma’s JAK1/TYK2 Inhibitor Proposed for Breakthrough Therapy Designation in

Date： 2026-06-25

June 24, 2026 – HighLight Pharma's JAK1/TYK2 inhibitor TLL-018 has been proposed for inclusion in the Breakthrough Therapy Designation (BTD) program for the treatment of rheumatoid arthritis.

Founded in 2017, HighLight Pharma focuses on developing innovative therapies for autoimmune and inflammatory diseases. Its lead asset, TLL-018, is a highly selective JAK1/TYK2 inhibitor. The drug is currently undergoing two pivotal Phase III registrational trials for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), both of which have met their primary endpoints. The company is also exploring multiple additional autoimmune indications. Its pipeline further includes TLL-041, a brain-penetrant JAK1/TYK2 inhibitor, as well as NLRP3 inhibitors and a highly selective brain-penetrant LRRK2 inhibitor.

Efung Capital participated in HighLight Pharma's financing rounds in 2020 and 2021. Looking ahead, Feng Capital will continue to deepen its dual-drive strategy of "industrial capital + professional empowerment," supporting HighLight Pharma in accelerating global multi-center clinical trials for core pipelines including TLL-041.

Previous:NoNext：Efung News | The First and Only One in C

Related News / Recommended news More

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

2026 - 03 - 24

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...

Frontier Biotechnologies Enters Exclusive License Agreement with GSK for siRNA Pipeline Products

2026 - 03 - 25

Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio News

2026 - 03 - 06

Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...

Viestar’s Confocal Microscopy Products Selected as Outstanding Domestic Medical Equipment

2026 - 03 - 05

The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...